Deciphera up as Stifel doubles sales estimates for tumor drug candidate

Deciphera Pharmaceuticals

27/09/2022 15:53

** Shares of Deciphera Pharmaceuticals Inc  DCPH.O  gain
3.7% to $18.23 
    ** Stifel raises sales estimates for co's drug candidate,
vimseltinib, for treating a rare type of benign tumor,
tenosynovial giant cell tumor (TGCT), by 112% 
    ** Brokerage lifts PT to $18 from $11 
    ** Stifel expects vimseltinib can emerge as a clear winner
over Daiichi Sankyo's  4568.T  Turalio for treating TGCT if it
is approved without a black-box warning, unlike Turalio
    ** Raises forecast for global sales opportunity  for the
drug to ~$100 mln
    ** However, brokerage adds increase in drug's sales
estimates is not sufficient to recommend the stock from current
levels after it recently doubled on elevated expectations
    ** Five of 11 brokerages rate the stock "buy" or higher, 4
"hold" and 2 "sell" or lower; their median PT is $18 - Refinitiv
data
    ** Including session moves, stock up ~87% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))